サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1423782

皮膚および全身性リーシュマニア症の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別

Cutaneous and Systemic Leishmaniasis Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 215 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
皮膚および全身性リーシュマニア症の世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）- 薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別
出版日: 2024年01月24日
発行: Fairfield Market Research
ページ情報: 英文 215 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界の皮膚および全身性リーシュマニア症の市場規模は、予測期間の2024年から2031年にかけて上昇基調にあります。この成長は、市場拡大を牽引するいくつかの主要因によるものと考えられます。

皮膚および全身性リーシュマニア症市場の成長を後押しする極めて重要な要因の1つは、併用薬物療法によって達成される印象的な臨床治癒率です。様々な薬剤の併用が非常に効果的であることが証明されており、中には完全治癒に至る組み合わせもあります。この有望な側面は、予測期間を通じて市場の成長を維持すると予想されます。

皮膚および全身性リーシュマニア症市場の多くの利害関係者は、革新的な治療法の開発を目的とした研究開発に多額の投資を行っています。現在進行中の様々な薬剤や治療法の臨床試験は有望な結果を示しており、皮膚および全身性リーシュマニア症治療の新たな可能性を開くものと期待されています。

世界各国の政府はヘルスケアインフラに多額の投資を行っており、市場の成長に貢献しています。さらに、民間の医療保険プロバイダーが有利な償還政策を提供しているため、患者は自分のニーズに最適なプランを選択することができ、治療へのアクセスがさらに容易になっています。

皮膚および全身性リーシュマニア症の治療費は、高価な薬剤のため依然として比較的高額であり、これらの治療法には深刻な副作用が生じる可能性があります。とはいえ、現在進行中の研究開発努力により、将来的にはより費用対効果が高く、安全な治療法が生み出されることが期待されています。

皮膚および全身性リーシュマニア症市場は競争が激しく、大手企業が業界を支配しているのが特徴です。市場参入企業は、増大する需要に対応し、地域市場での優位性を確立するため、技術提携、販売代理店契約、研究開発の強化、製品の発売など、新しく革新的な戦略を取り入れています。

当レポートでは、世界の皮膚および全身性リーシュマニア症市場について調査し、市場の概要とともに、薬剤クラス別、投与経路別、適応症別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界の皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

  • 世界の皮膚および全身性リーシュマニア症市場の見通し、薬剤クラス別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚および全身性リーシュマニア症市場の見通し、投与経路別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚および全身性リーシュマニア症市場の見通し、適応症別、金額（10億米ドル）、2018年～2031年
  • 世界の皮膚および全身性リーシュマニア症市場の見通し、流通チャネル別、金額（米国米ドル）、2018年～2031年
  • 世界の皮膚および全身性リーシュマニア症市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米の皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

第5章 欧州の皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

第6章 アジア太平洋の皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

第7章 ラテンアメリカの皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

第8章 中東・アフリカの皮膚および全身性リーシュマニア症市場の見通し、2018年～2031年

第9章 競合情勢

  • 薬剤クラスと適応症のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • Gilead Sciences, Inc.
    • Profounda Pharmaceuticals
    • Knight Therapeutics Inc.
    • Janssen Global Services, LLC
    • Albert David Ltd
    • Jubilant Life Sciences Ltd.
    • Novartis AG
    • Sanofi
    • Endo Pharmaceuticals Inc
    • Bristol-Myers Squibb Company
    • United Biotech Pvt. Ltd.

第10章 付録

目次

The global Cutaneous and Systemic Leishmaniasis market is on an upward trajectory over the forecast period 2024-2031. This growth can be attributed to several key factors that are driving the market's expansion.

High Clinical Cure Rate with Combinational Drug Therapy

One of the pivotal factors fueling the growth of the Cutaneous and Systemic Leishmaniasis market is the impressive clinical cure rate achieved through combinational drug therapy. The use of various drug combinations has proven to be highly effective, with some combinations even resulting in complete cures. This promising aspect is expected to sustain the market's growth throughout the forecast period.

Increased Investments for Research And Development

Numerous stakeholders in the Cutaneous and Systemic Leishmaniasis market are making substantial investments in research and development efforts aimed at developing innovative treatment alternatives. Ongoing clinical trials for a wide range of drugs and therapies show promising outcomes, which are anticipated to open up new opportunities for treating cutaneous and systemic leishmaniasis.

Favorable Reimbursement Policies

Governments worldwide are significantly investing in healthcare infrastructure, contributing to the growth of the market. Additionally, private health insurance providers are offering favorable reimbursement policies, allowing patients to choose plans that best suit their needs, further facilitating access to treatment.

However, the market does face some challenges:

High Cost of Treatment and Chances Of Side Effects

The cost of treating Cutaneous and Systemic Leishmaniasis remains relatively high due to expensive drugs, and these treatments may have serious side effects. Nevertheless, ongoing research and development efforts are expected to yield more cost-effective and safer treatment options in the future.

Impact of COVID-19

The COVID-19 pandemic initially led to a decrease in demand for Cutaneous & Systemic Leishmaniasis treatment due to healthcare facilities' overwhelming focus on managing the pandemic. However, as the situation improved in 2021, demand for these treatments started to rebound.

Competitive Analysis

The Cutaneous and Systemic Leishmaniasis market is fiercely competitive and is characterized by major players dominating the industry. Market participants are embracing new and innovative strategies, including technological collaborations, distributorship agreements, increased research and development, and product launches, to meet growing demand and establish their dominance in regional markets.

Key Companies Profiled

  • Gilead Sciences, Inc.
  • Profounda Pharmaceuticals
  • Knight Therapeutics Inc.
  • Janssen Global Services, LLC
  • Albert David Ltd
  • Jubilant Life Sciences Ltd.
  • Novartis AG
  • Sanofi
  • Endo Pharmaceuticals Inc
  • Bristol-Myers Squibb Company
  • United Biotech Pvt. Ltd.

As the Cutaneous & Systemic Leishmaniasis market continues to grow and evolve, these key players are at the forefront of driving advancements in research, development, and access to treatment, ensuring a brighter future for those affected by this disease.

Cutaneous and Systemic Leishmaniasis Market Categorization

Cutaneous and Systemic Leishmaniasis Market by By Drug Class

  • Pentavalent Antimonials
  • Antifungal Drugs
  • Anti-Lesihmanial/Antimicrobial Drugs

Cutaneous and Systemic Leishmaniasis Market By Route of Administration

  • Oral
  • Injectable
  • Topical

Cutaneous and Systemic Leishmaniasis Market By Indication

  • Cutaneous Leishmaniasis
  • Mucosal Leishmaniasis
  • Visceral Leishmaniasis

Cutaneous and Systemic Leishmaniasis Market By Distribution Channel

  • Hospital Pharmacies,
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Cutaneous and Systemic Leishmaniasis Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Cutaneous and Systemic Leishmaniasis Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 3.1. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pentavalent Antimonials
      • 3.1.1.2. Antifungal Drugs
      • 3.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 3.2. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Injectable
      • 3.2.1.3. Topical
  • 3.3. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Cutaneous Leishmaniasis
      • 3.3.1.2. Mucosal Leishmaniasis
      • 3.3.1.3. Visceral Leishmaniasis
  • 3.4. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies,
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Cutaneous and Systemic Leishmaniasis Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 4.1. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pentavalent Antimonials
      • 4.1.1.2. Antifungal Drugs
      • 4.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 4.2. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Injectable
      • 4.2.1.3. Topical
  • 4.3. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Cutaneous Leishmaniasis
      • 4.3.1.2. Mucosal Leishmaniasis
      • 4.3.1.3. Visceral Leishmaniasis
  • 4.4. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies,
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 5.1. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pentavalent Antimonials
      • 5.1.1.2. Antifungal Drugs
      • 5.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 5.2. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Injectable
      • 5.2.1.3. Topical
  • 5.3. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Cutaneous Leishmaniasis
      • 5.3.1.2. Mucosal Leishmaniasis
      • 5.3.1.3. Visceral Leishmaniasis
  • 5.4. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies,
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pentavalent Antimonials
      • 6.1.1.2. Antifungal Drugs
      • 6.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 6.2. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Injectable
      • 6.2.1.3. Topical
  • 6.3. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Cutaneous Leishmaniasis
      • 6.3.1.2. Mucosal Leishmaniasis
      • 6.3.1.3. Visceral Leishmaniasis
  • 6.4. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies,
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 7.1. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pentavalent Antimonials
      • 7.1.1.2. Antifungal Drugs
      • 7.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 7.2. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Injectable
      • 7.2.1.3. Topical
  • 7.3. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Cutaneous Leishmaniasis
      • 7.3.1.2. Mucosal Leishmaniasis
      • 7.3.1.3. Visceral Leishmaniasis
  • 7.4. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies,
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pentavalent Antimonials
      • 8.1.1.2. Antifungal Drugs
      • 8.1.1.3. Anti-Lesihmanial/Antimicrobial Drugs
  • 8.2. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Injectable
      • 8.2.1.3. Topical
  • 8.3. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Cutaneous Leishmaniasis
      • 8.3.1.2. Mucosal Leishmaniasis
      • 8.3.1.3. Visceral Leishmaniasis
  • 8.4. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies,
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Cutaneous and Systemic Leishmaniasis Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Drug Class, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Cutaneous and Systemic Leishmaniasis Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Class vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Gilead Sciences, Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Profounda Pharmaceuticals
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Knight Therapeutics Inc.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Janssen Global Services, LLC
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Albert David Ltd
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Jubilant Life Sciences Ltd.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novartis AG
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Sanofi
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Endo Pharmaceuticals Inc
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. United Biotech Pvt. Ltd.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations